Current treatment options for Dientamoeba fragilis infections

Area of Science:

• Medical Parasitology
• Gastroenterology
• Infectious Diseases

Background:

• Dientamoeba fragilis is a protozoan parasite implicated in gastrointestinal disease.
• Prevalence ranges globally from 0.5% to 16%, often causing chronic diarrhea.
• Current treatment knowledge relies heavily on small case reports.

Purpose of the Study:

• To critically review all available treatment options for Dientamoeba fragilis infections (dientamoebiasis).
• To highlight the need for further research due to limited large-scale clinical trials and in vitro data.

Main Methods:

• Literature review of studies reporting successful parasite clearance and symptom resolution.
• Analysis of reported antiparasitic compounds used for treatment.
• Assessment of existing data on treatment efficacy and in vitro susceptibility.

Main Results:

• Numerous antiparasitic compounds have shown success in case reports, including carbarsone, tetracyclines, erythromycin, and 5-nitroimidazoles (metronidazole, tinidazole).
• Most treatment data is derived from limited case reports, lacking robust clinical trial evidence.
• There is a significant lack of in vitro susceptibility data for D. fragilis, questioning the efficacy of some current treatments.

Conclusions:

• While several treatments show promise in case studies, robust evidence from large-scale, placebo-controlled trials is lacking.
• The efficacy of current treatment options for Dientamoeba fragilis remains questionable due to insufficient data.
• Further research, including in vitro susceptibility testing and randomized controlled trials, is crucial for establishing evidence-based treatment guidelines.